Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium-177 anti-EGFRvIII
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intracavitary
01
Overview
Lutetium-177 anti-EGFRvIII is a radioimmunotherapy agent consisting of a monoclonal antibody (such as the L8A4 clone) labeled with the therapeutic radioisotope lutetium-177. It is designed to target the epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific mutation found in glioblastomas and other gliomas but not in normal tissues. The antibody binds to the extracellular domain of EGFRvIII and is rapidly internalized, delivering targeted beta radiation from the lutetium-177 isotope directly to the tumor cells. This therapeutic approach is particularly focused on treating residual tumor cells at the margins of the surgical cavity following the debulking of brain tumors. Various bifunctional chelators, including 1B4M-DTPA and MeO-DOTA, have been utilized to optimize the stability and biodistribution of the radiopharmaceutical.
- Other names
- Lutetium-177 L8A4Lutetium177 L8A4Lutetium 177 L8A4177Lu-labeled L8A4177Lu-1B4M-DTPA-L8A4177Lu-MeO-DOTA-L8A4
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on lutetium-177 anti-EGFRvIII.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium-177 anti-EGFRvIII.